

Christopher Em Griffiths

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10684042/publications.pdf>

Version: 2024-02-01

49
papers

10,784
citations

159358

30
h-index

223531

46
g-index

50
all docs

50
docs citations

50
times ranked

8704
citing authors

#	ARTICLE	IF	CITATIONS
1	How do dermatologists' personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast). <i>British Journal of Dermatology</i> , 2022, , .	1.4	2
2	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. <i>Programme Grants for Applied Research</i> , 2022, 10, 1-240.	0.4	0
3	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1872-1878.	0.3	4
4	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	0.6	71
5	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2120-2130.	1.5	128
6	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 70-79.e3.	0.6	77
7	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 277-286.e10.	0.6	163
8	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018, 138, 775-784.	0.3	71
9	Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis. <i>Value in Health</i> , 2018, 21, 1010-1018.	0.1	16
10	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 405-417.	0.6	673
11	The challenges of assessing patients' medication beliefs: a qualitative study. <i>BMC Health Services Research</i> , 2017, 17, 119.	0.9	13
12	Inhibition of IL-17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections. <i>Clinical and Translational Immunology</i> , 2017, 6, e152.	1.7	67
13	Feeding filaggrin: effects of L-histidine supplementation in atopic dermatitis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2017, Volume 10, 403-411.	0.8	38
14	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 83-98.e4.	0.6	264
15	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1584-1591.	0.3	63
16	Interleukin 17-A inhibition in the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1-4.	1.3	28
17	I should have taken that further' missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed-methods study. <i>Health Expectations</i> , 2016, 19, 1121-1137.	1.1	28
18	Novel systemic therapies for the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 79-92.	0.9	18

#	ARTICLE	IF	CITATIONS
19	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2015, 135, 2632-2640.	0.3	318
20	Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2189-2197.	0.3	132
21	Responsiveness to Change and Interpretability of the Simplified Psoriasis Index. <i>Journal of Investigative Dermatology</i> , 2014, 134, 351-358.	0.3	32
22	Polymorphisms in IL-1B Distinguish between Psoriasis of Early and Late Onset. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1459-1462.	0.3	26
23	Drug therapies in dermatology. <i>Clinical Medicine</i> , 2014, 14, 47-53.	0.8	7
24	Secukinumab in Plaque Psoriasis – Results of Two Phase 3 Trials. <i>New England Journal of Medicine</i> , 2014, 371, 326-338.	13.9	1,675
25	Can stress reduction interventions improve psoriasis? A review. <i>Psychology, Health and Medicine</i> , 2013, 18, 501-514.	1.3	29
26	Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. <i>Journal of Investigative Dermatology</i> , 2013, 133, 377-385.	0.3	1,827
27	Biologic therapies in dermatology. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 12-17.	0.2	0
28	“On the surface”: a qualitative study of GPs’ and patients’ perspectives on psoriasis. <i>BMC Family Practice</i> , 2013, 14, 158.	2.9	55
29	Beyond skin: the need for a new approach to the management of psoriasis in primary care. <i>British Journal of General Practice</i> , 2012, 62, 568-569.	0.7	15
30	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 731-741.	0.6	101
31	Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 2-8.	1.3	8
32	Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial. <i>Dermatology</i> , 2010, 221, 172-178.	0.9	55
33	Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. <i>New England Journal of Medicine</i> , 2010, 362, 118-128.	13.9	773
34	The Future of Biological Therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 63-66.	1.6	18
35	Genetic susceptibility to psoriasis: an emerging picture. <i>Genome Medicine</i> , 2009, 1, 72.	3.6	14
36	Adalimumab for the treatment of psoriasis. <i>Expert Review of Dermatology</i> , 2009, 4, 15-21.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1925-1929.	0.3	109
38	Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 224-231.	0.6	157
39	Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility gene. <i>Human Molecular Genetics</i> , 2008, 17, 1938-1945.	1.4	176
40	The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. <i>Journal of Clinical Investigation</i> , 2008, 118, 3151-3159.	3.9	145
41	Pathogenesis and clinical features of psoriasis. <i>Lancet, The</i> , 2007, 370, 263-271.	6.3	1,617
42	Current and future management of psoriasis. <i>Lancet, The</i> , 2007, 370, 272-284.	6.3	268
43	Biological therapy for psoriasis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2006, 67, 184-187.	0.2	2
44	Infliximab for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 797-805.	1.4	37
45	Impaired Langerhans cell migration in psoriasis. <i>Journal of Experimental Medicine</i> , 2006, 203, 953-960.	4.2	109
46	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. <i>Lancet, The</i> , 2005, 366, 1367-1374.	6.3	975
47	Divergent Beliefs About Psoriasis Are Associated with Increased Psychological Distress. <i>Journal of Investigative Dermatology</i> , 2004, 123, 49-56.	0.3	50
48	Single-Nucleotide Polymorphisms of Vascular Endothelial Growth Factor in Psoriasis of Early Onset. <i>Journal of Investigative Dermatology</i> , 2004, 122, 209-215.	0.3	138
49	Genetic Analysis of PSORS1 Distinguishes Guttate Psoriasis and Palmoplantar Pustulosis. <i>Journal of Investigative Dermatology</i> , 2003, 120, 627-632.	0.3	190